Browse ALDH6A1

Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion.
Domain PF00171 Aldehyde dehydrogenase family
Function

Plays a role in valine and pyrimidine metabolism. Binds fatty acyl-CoA.

> Gene Ontology
 
Biological Process GO:0006206 pyrimidine nucleobase metabolic process
GO:0006208 pyrimidine nucleobase catabolic process
GO:0006210 thymine catabolic process
GO:0006520 cellular amino acid metabolic process
GO:0006573 valine metabolic process
GO:0006574 valine catabolic process
GO:0009063 cellular amino acid catabolic process
GO:0009081 branched-chain amino acid metabolic process
GO:0009083 branched-chain amino acid catabolic process
GO:0009112 nucleobase metabolic process
GO:0016054 organic acid catabolic process
GO:0019859 thymine metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044282 small molecule catabolic process
GO:0045444 fat cell differentiation
GO:0046113 nucleobase catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0046700 heterocycle catabolic process
GO:0050873 brown fat cell differentiation
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0000062 fatty-acyl-CoA binding
GO:0004029 aldehyde dehydrogenase (NAD) activity
GO:0004491 methylmalonate-semialdehyde dehydrogenase (acylating) activity
GO:0016620 oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
GO:0016903 oxidoreductase activity, acting on the aldehyde or oxo group of donors
GO:0018478 malonate-semialdehyde dehydrogenase (acetylating) activity
GO:0048037 cofactor binding
GO:0050662 coenzyme binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00280 Valine, leucine and isoleucine degradation
hsa00410 beta-Alanine metabolism
hsa00562 Inositol phosphate metabolism
hsa00640 Propanoate metabolism
hsa01100 Metabolic pathways
hsa01200 Carbon metabolism
Reactome R-HSA-70895: Branched-chain amino acid catabolism
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ALDH6A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ALDH6A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ALDH6A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8080.0303
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7750.552
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8310.412
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3020.351
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1960.912
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9240.652
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2050.611
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.590.591
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3040.817
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3460.784
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4910.77
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0030.971
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ALDH6A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALDH6A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALDH6A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALDH6A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALDH6A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ALDH6A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ALDH6A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolALDH6A1
Namealdehyde dehydrogenase 6 family, member A1
Aliases MMSDH; MMSADHA; malonate-semialdehyde dehydrogenase; mitochondrial acylating methylmalonate-semialdehyde deh ......
Chromosomal Location14q24.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ALDH6A1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ALDH6A1.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144